Grin2A expression under inhibition of miR-17 in poststroke depression rats

doi:10.3969/j.issn.2095-4344.2015.24.012

Abstract

Abstract:

BACKGROUND: Poststroke depression is one of the most common psychological behavior disorders after stroke and its mechanism remains unclear. Studies have suggested that microRNAs (miRNAs) involved in neurogenesis and synaptogenesis may play an important role in psychology diseases.
OBJECTIVE: To observe the expression of miR-137 in the blood and brain of poststroke depression rats and its effect on the behaviors of rats.
METHODS: Thirty-six rats were equally divided into six groups: control, model, agomir-137, agomir-NC, agomir-137 + Grin2A and agomir-137+vector groups. Control group had no treatment. Poststroke depression models were established by ligation of middle cerebral artery and chronic mild stimulation in the latter four groups followed by receiving an injection of nothing, agomir-137, agomir-NC, LV-CMV-Grin2A or control plasmids into the left lateral ventricle, respectively.
RESULTS AND CONCLUSION: We found significantly lower miR-137 levels in the brain and peripheral blood of post-stroke depression rats compared with normal rats. Vertical scores and horizontal scores on the behavior test were significantly higher in the agomir-137 group than the agomir-NC and model groups at 3 weeks after cerebral ischemia; while, sucrose consumption percentage was also higher in the agomir-137 group at the end of 2 weeks
after cerebral ischemia. Luciferase assays showed miR-137 bound to the 3’ UTR of Grin2A, regulating Grin2A expression in a neuronal cell line. Grin2A gene overexpression in the brain of post-stroke depression rats noticeably suppressed the inhibitory effect of miR-137 on post-stroke depression. Overall, these findings show that miR-137 suppresses Grin2A protein expression through binding to Grin2A mRNA, thereby exerting an inhibitory effect on post-stroke depression and offering a new therapeutic target for poststroke depression.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

CLC Number:

R318

Yang Xiao-yu, Shi Qi, Chu Xiu-feng, Zhang Qing-qin, Zhang Min, Zheng Sheng-zhe, Ji Ying-hua,Lu Ping. Grin2A expression under inhibition of miR-17 in poststroke depression rats [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(24): 3832-3838.

Figures/Tables 3

References

[1] Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry. 2002;52(3):253-264.

[2] Souza AC, Rocha MO, Teixeira AL, et al. Depressive symptoms and disability in chagasic stroke patients: impact on functionality and quality of life. J Neurol Sci. 2013;324(1-2): 34-37.

[3] Hama S, Yamashita H, Yamawaki S, et al. Post-stroke depression and apathy: Interactions between functional recovery, lesion location, and emotional response. Psychogeriatrics. 2011;11(1):68-76.

[4] Farner L, Wagle J, Engedal K, et al. Depressive symptoms in stroke patients: a 13 month follow-up study of patients referred to a rehabilitation unit. J Affect Disord. 2010;127(1-3): 211-218.

[5] Van Wynsberghe PM, Chan SP, Slack FJ, et al. Analysis of microRNA expression and function. Methods Cell Biol. 2011; 106:219-252.

[6] Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet. 2011;12(12):846-860.

[7] Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515-524.

[8] Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172-1187.

[9] Smalheiser NR, Lugli G, Rizavi HS, et al. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One. 2012;7(3): e33201.

[10] Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, et al. Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013;23(7):602-611.

[11] Baudry A, Mouillet-Richard S, Schneider B, et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010;329(5998): 1537-1541.

[12] Mouillet-Richard S, Baudry A, Launay JM, et al. MicroRNAs and depression. Neurobiol Dis. 2012;46(2):272-278.

[13] O'Connor RM, Dinan TG, Cryan JF. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol Psychiatry. 2012;17(4):359-376.

[14] Tan KS, Armugam A, Sepramaniam S, et al. Expression profile of MicroRNAs in young stroke patients. PLoS One. 2009;4(11):e7689.

[15] Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke. 2008; 39(3):959-966.

[16] Dharap A, Vemuganti R. Ischemic pre-conditioning alters cerebral microRNAs that are upstream to neuroprotective signaling pathways. J Neurochem. 2010;113(6):1685-1691.

[17] Nishida F, Morel GR, Hereñú CB, et al. Restorative effect of intracerebroventricular insulin-like growth factor-I gene therapy on motor performance in aging rats. Neuroscience. 2011;177:195-206.

[18] Hahn CD, Manlhiot C, Schmidt MR, et al. Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke. 2011;42(10):2960-2962.

[19] Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84-91.

[20] Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005;52(2):90-110.

[21] Wang SH, Zhang ZJ, Guo YJ, et al. Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression. Psychiatry Res. 2009;170(2-3):245-251.

[22] Duan Q, Wang X, Gong W, et al. ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One. 2012;7(2):e31518.

[23] Geekiyanage H, Jicha GA, Nelson PT, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol. 2012;235(2):491-496.

[24] Smrt RD, Szulwach KE, Pfeiffer RL, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells. 2010;28(6):1060-1070.

[25] Cummings E, Donohoe G, Hargreaves A, et al. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci Lett. 2013;532:33-38.

[26] Kwon E, Wang W, Tsai LH. Validation of schizophrenia- associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry. 2013;18(1):11-12.

[27] Mozhui K, Karlsson RM, Kash TL, et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J Neurosci. 2010;30(15):5357-5367.

[28] Reutlinger C, Helbig I, Gawelczyk B, et al. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia. 2010;51(9):1870-1873.

[29] Cherlyn SY, Woon PS, Liu JJ, et al. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev. 2010;34(6):958-977.

[30] Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci. 2011;33(8):1351-1365.

[31] Szakacs R, Janka Z, Kalman J. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression. Neuropsychopharmacol Hung. 2012;14(1):29-40.

[32] Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-95.

[33] Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169(11):1150-1156.

[34] Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry. 2013;73(12):1199-1203.

[35] Naughton M, Clarke G, O'Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014;156: 24-35.

[36] Castillo CS, Schultz SK, Robinson RG. Clinical correlates of early-onset and late-onset poststroke generalized anxiety. Am J Psychiatry. 1995;152(8):1174-1179.

[37] Cam E, Yulug B, Ozan E. MK 801: a possible neuroprotective agent by poststroke depression? J Neuropsychiatry Clin Neurosci. 2008;20(3):367-368.

[38] Robinson RG, Jorge RE, Clarence-Smith K, et al. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009;21(2):144-151.

[39] Hama S, Yamashita H, Yamawaki S, et al. Post-stroke depression and apathy: Interactions between functional recovery, lesion location, and emotional response. Psychogeriatrics. 2011;11(1):68-76.

[40] Lim AL, Taylor DA, Malone DT. Consequences of early life MK-801 administration: long-term behavioural effects and relevance to schizophrenia research. Behav Brain Res. 2012;227(1):276-286.

[41] Pae CU, Marks DM, Han C, et al. Does neurotropin-3 have a therapeutic implication in major depression? Int J Neurosci. 2008;118(11):1515-1522.

[42] Yulug B. Neuroprotective treatment strategies for poststroke mood disorders: A minireview on atypical neuroleptic drugs and selective serotonin re-uptake inhibitors. Brain Res Bull. 2009;80(3):95-99.

[43] Buller KM, Carty ML, Reinebrant HE, et al. Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate? J Neurosci Res. 2009;87(3):599-608

[44] Meloni BP, Campbell K, Zhu H, et al. In search of clinical neuroprotection after brain ischemia: the case for mild hypothermia (35 degrees C) and magnesium. Stroke. 2009; 40(6):2236-2240.